Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US90400D1081
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG001RWPDW6
RARE
Ultragenyx Pharmaceutical Inc
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Ultragenyx Pharmaceutical Inc
ISIN
US90400D1081
TICKER
RARE
MIC
XNAS
REUTERS
RARE.OQ
BLOOMBERG
RARE US
Fr., 19.06.2026       Ultragenyx Pharmaceutical
US90400D1081

NOVATO, Calif., June 19, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 44,409 restricted stock units of the company’s common stock to 15 newly hired non-executive o...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 04.06.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK, June 4, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) breached their fiduciary duties to shareholders....
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mi., 03.06.2026       Ultragenyx Pharmaceutical
US90400D1081

NOVATO, Calif., June 03, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Emil Kakkis, M.D., Ph.D., the company's president and chief executive officer will p...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 01.06.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - June 1, 2026) - Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) breached their fiduciary duties to shareholders. According to a federal securities lawsuit, Insiders at Ultragenyx Pharmaceutical caused t...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Fr., 22.05.2026       Ultragenyx Pharmaceutical
US90400D1081

NOVATO, Calif., May 22, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 17,567 restricted stock units of the company’s common stock to 11 newly hired non-executive of...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mi., 06.05.2026       Ultragenyx Pharmaceutical
US90400D1081

NOVATO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced that Howard Horn, the company's Chief Financial Officer and Executive Vice President and J...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Fr., 24.04.2026       Ultragenyx Pharmaceutical
US90400D1081

NOVATO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 36,447 restricted stock units of the company’s common stock to 12 newly hired non-executive...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mi., 08.04.2026       Ultragenyx Pharmaceutical
US90400D1081

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 06.04.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - April 6, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 06.04.2026       Ultragenyx Pharmaceutical
US90400D1081

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Ultragenyx Pharmaceutical Inc (“Ultragenyx” or the “Company”) (NASDAQ: RARE) and reminds investors of the April 6, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company....
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mo., 06.04.2026       Ultragenyx Pharmaceutical
US90400D1081

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereu...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 06.04.2026       Ultragenyx Pharmaceutical
US90400D1081

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commissio...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
So., 05.04.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - April 5, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
So., 05.04.2026       Ultragenyx Pharmaceutical
US90400D1081

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Sa., 04.04.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK, April 4, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusiv...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Sa., 04.04.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - April 4, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Sa., 04.04.2026       Ultragenyx Pharmaceutical
US90400D1081

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Sa., 04.04.2026       Ultragenyx Pharmaceutical
US90400D1081

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 6, 2026 to file lead plaintiff applications in a securities class action lawsuit against Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NasdaqGS: RARE), if they purchased or...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Fr., 03.04.2026       Ultragenyx Pharmaceutical
US90400D1081

Rosen Law Firm, a global investor rights law firm, reminds investors about a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025. Ultragenyx describes itself as a “biopharmaceutical company focused on rare and ultrarare genetic disorders.” For...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Fr., 03.04.2026       Ultragenyx Pharmaceutical
US90400D1081

PHILADELPHIA, April 3, 2026 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") on behalf of investors who purchased common shares of Ultragenyx during the period from August 3, 2023 through Decemb...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 03.04.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - April 3, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 02.04.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire b...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 02.04.2026       Ultragenyx Pharmaceutical
US90400D1081

If approved, UX111 will be the first approved therapy for the treatment of Sanfilippo syndrome Type A, a rare disease affecting young children that leads to progressive, irreversible neurodegeneration and early death...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 02.04.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - April 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purch...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mi., 01.04.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK, April 1, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mi., 01.04.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - March 31, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Di., 31.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Di., 31.03.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK, March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Shareholders who purchased shares of RARE during the class period listed are enc...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK, March 30, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline....
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Philadelphia, Pennsylvania--(Newsfile Corp. - March 30, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") on behalf of investors who purchased Ultragenyx common stock during the period from August 3, 2023...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       Ultragenyx Pharmaceutical
US90400D1081

LOS ANGELES, March 30, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commissi...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       Ultragenyx Pharmaceutical
US90400D1081

LOS ANGELES, March 30, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ: RARE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated there...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 30.03.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - March 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purc...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
So., 29.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
So., 29.03.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - March 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.SO WHAT: If you...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Sa., 28.03.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK and NEW ORLEANS, March 27, 2026 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NasdaqGS: RARE) of a class action securities lawsuit.   CLASS DEFINI...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Fr., 27.03.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - March 27, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Fr., 27.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 26.03.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - March 26, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 26.03.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquir...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Do., 26.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mi., 25.03.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK, March 25, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusi...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mi., 25.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) common stock between August 3, 2023 and December 26, 2025. Ultragenyx is a biopharmaceutical company focused on rare and ultrarare genetic disorders. For more information, sub...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mi., 25.03.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK, March 25, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mi., 25.03.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - March 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Di., 24.03.2026       Ultragenyx Pharmaceutical
US90400D1081

NEW YORK, March 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). Shareholders who purchased shares of RARE during the class period listed are enc...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Di., 24.03.2026       Ultragenyx Pharmaceutical
US90400D1081

New York, New York--(Newsfile Corp. - March 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline. SO WHAT: If you purc...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 23.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi par...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
Mo., 23.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Philadelphia, Pennsylvania--(Newsfile Corp. - March 23, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) ("Ultragenyx" or the "Company") on behalf of investors who purchased common shares of Ultragenyx during the period from August 3,...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink
So., 22.03.2026       Ultragenyx Pharmaceutical
US90400D1081

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi pa...
Zur Nachricht
Ultragenyx Pharmaceutical
Charts & Research Termsheets Terminal
Permalink